Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Commvault Systems Inc (CVLT) vs TransMedics Group Inc (TMDX) Price & Performance

Commvault Systems IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Commvault Systems Inc vs TransMedics Group Inc — how do they compare? Commvault Systems Inc trades at $140.6 (market cap $5.78B), while TransMedics Group Inc trades at $87.29 (market cap $3.10B). The key difference: Commvault Systems Inc is the larger of the two by market cap, and Commvault Systems Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.

CVLTTMDX
Market Cap
$5.78B$3.10B
Sector
TechnologyTechnology
52-Week High
$195.41$150.42
52-Week Low
$75.18$61.99
Enterprise Value
$5.76B$3.49B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Commvault Systems Inc

Commvault Systems (CVLT) trades at $140.52, up 0.78% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats, 81% gross margins, and 32.77% ROE, though valuation metrics appear elevated with P/E at 89.35. Recent news highlights positive developments including Threat Scan integration with Google and strong Q1 2027 results with 16% subscription revenue growth.

CVLT presents growth potential with 22% ARR growth and analyst consensus target of $172.40 (23% upside), but faces risks from fiduciary investigations and high valuation multiples. The stock's technical strength and fundamental execution support bullish sentiment, though investors should monitor the ongoing legal scrutiny and margin compression from 7.64% to 5.61% net margin projection.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.

The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.

Returns comparison

Trailing returns across standard periods

About Commvault Systems Inc

Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.

Read more on CVLT

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX